Anti hypertensives in preganacy
Reading File
Finding Sources
Finding Sources
Searching PubMed
"antihypertensive agents"[MeSH Terms] AND "pregnancy"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Antihypertensives in Pregnancy
Hypertension complicates >10% of pregnancies and is one of the leading causes of maternal and perinatal morbidity. Drug selection requires balancing maternal BP control with fetal safety, as some agents are teratogenic and others reduce uteroplacental perfusion.
Classification of Hypertension in Pregnancy
| Type | Definition |
|---|---|
| Chronic hypertension | Pre-existing or diagnosed before 20 weeks |
| Gestational hypertension | New-onset ≥20 weeks, no proteinuria/organ damage |
| Preeclampsia | ≥20 weeks + proteinuria or target organ damage |
| HELLP syndrome | Hemolysis + elevated liver enzymes + low platelets |
| Eclampsia | Preeclampsia + seizures |
| Superimposed preeclampsia | Preeclampsia on chronic hypertension |
When to Treat
-
Severe hypertension (SBP ≥160 or DBP ≥105-110 mm Hg): treatment is clearly indicated to prevent stroke and maternal cardiovascular complications.
-
Mild-to-moderate hypertension: more controversial. ACOG (2013) recommended against treatment for BP <160/105 in chronic hypertension without end-organ damage, as aggressive lowering may impair fetal growth via reduced uteroplacental perfusion.
-
The CHIPS trial showed that "tight" control (target DBP 85 mm Hg) vs. "less-tight" (DBP 100 mm Hg) reduced maternal complications (severe hypertension, thrombocytopenia, transaminitis) without significant difference in neonatal outcomes.
-
NICE 2019 recommends initiating treatment at >140/90 with a target of 110-135/70-85 mm Hg.
-
Brenner & Rector's The Kidney, p. 2159 | Comprehensive Clinical Nephrology, 7th Ed., p. 631
First-Line Oral Agents
1. Alpha-Methyldopa (Methyldopa)
- Class: Centrally acting alpha-2 agonist
- Dose: 250 mg to 1.5 g orally twice daily
- FDA category: B
- Mechanism: Depletes nerve terminal norepinephrine, reducing peripheral resistance and venous constriction
- Why preferred: Only drug with long-term follow-up data in offspring (up to 7.5 years) - no neurologic or somatic abnormalities
- Cautions: Fatigue, orthostatic hypotension; ferrous sulfate (iron supplementation) impairs absorption and can raise BP; less effective for severe hypertension than beta-blockers
2. Labetalol
- Class: Combined alpha- and beta-adrenergic blocker
- Dose (oral): 100-1200 mg/day
- FDA category: C
- Mechanism: Reduces heart rate and SVR; preserves placental flow; no significant sympathetic blockade in the neonate
- Benefits: Widely used; effective for both chronic therapy and acute BP control; some evidence it may be superior to methyldopa in preventing preeclampsia
- Cautions: Contraindicated in asthma; some reports of fetal growth restriction (primarily with atenolol, less so labetalol); avoid in decompensated cardiac failure
3. Nifedipine (Calcium Channel Blocker)
-
Class: Dihydropyridine CCB
-
Dose: 10-20 mg orally; extended-release preparations preferred for chronic use
-
FDA category: C
-
Benefits: Does not adversely affect uterine blood flow; increases renal perfusion
-
Caution: Possible additive neuromuscular blockade with magnesium sulfate (used for seizure prophylaxis in preeclampsia); can cause headache and uterine relaxation (may slow labor and cause postpartum atony)
-
Creasy & Resnik's Maternal-Fetal Medicine, pp. 1079-1081 | Harrison's Principles of Internal Medicine 22E, p. 2183
Second-Line Oral Agents
| Agent | Notes |
|---|---|
| Beta-blockers (metoprolol, propranolol) | Atenolol should be avoided - most clearly associated with IUGR; metoprolol preferred over atenolol (less placental crossing) |
| Thiazide diuretics (hydrochlorothiazide 12.5-50 mg/day) | Used with some frequency but risk volume depletion and hypokalemia; may not be ideal in preeclampsia where intravascular volume is already contracted |
Acute / IV Management of Severe Hypertension (BP ≥160/110 for ≥15 min)
This is a hypertensive emergency - goal is to reduce SBP to <160 and DBP to <110 without precipitous falls that could impair uteroplacental flow.
| Drug | Dose | Notes |
|---|---|---|
| IV Labetalol | 10-20 mg IV, repeat 20-80 mg q10-30 min; max 300 mg | First-line per ACOG; preserves placental flow; no neonatal sympathetic blockade |
| Oral Nifedipine | 10-20 mg orally, repeat in 20 min if needed | ACOG-endorsed; rapid onset; useful where IV access unavailable |
| IV Hydralazine | 5 mg IV, then 5-10 mg q20-40 min; max 20 mg | Arteriolar vasodilator; increases uterine and renal blood flow; but unpredictable onset/duration; meta-analysis (21 trials) shows increased risk of maternal hypotension, oliguria, placental abruption, and low Apgar scores vs. labetalol or nifedipine - now considered second-line |
| IV Nicardipine | 5 mg/hr infusion, titrate to max 30 mg/hr | Safe; smooth BP fall; increases renal perfusion |
| Sodium nitroprusside | 0.3 mcg/kg/min titrated | Reserved for refractory cases only; risk of fetal cyanide toxicity if used >4 hours; requires arterial line |
ACOG recommends consultation with MFM, anesthesiology, or critical care if first-line agents fail.
- Creasy & Resnik's Maternal-Fetal Medicine, p. 1735 | Brenner & Rector's The Kidney, p. 2162
Contraindicated Agents
| Drug | Reason |
|---|---|
| ACE inhibitors (e.g., enalapril, captopril) | Fetopathy (renal dysgenesis, oligohydramnios, skull hypoplasia, IUGR) in 2nd/3rd trimester - Class D; controversial in 1st trimester (Class C) |
| ARBs (e.g., losartan, valsartan) | Same mechanism as ACEi - Class D in 2nd/3rd trimester |
| Atenolol | Most clearly associated with intrauterine growth restriction |
| Nitroprusside (prolonged) | Fetal cyanide toxicity |
Antihypertensives in Breastfeeding
- Methyldopa: first-line; extensive safety data
- Labetalol, propranolol: preferred beta-blockers (high protein binding = less breast milk excretion); atenolol and metoprolol are concentrated in milk - avoid
- Diuretics: may suppress milk production - generally avoid
- ACE inhibitors (enalapril, captopril): poorly excreted in milk; generally safe; preferred in women with proteinuric renal disease post-delivery
- Brenner & Rector's The Kidney, p. 2162
Recent Evidence (2024-2025)
A 2025 network meta-analysis published in AJOG (PMID 40216176) evaluated oral antihypertensive treatments during pregnancy and is the most current comparative effectiveness data available. A 2024 systematic review (PMID 38488570) on anti-hypertensive therapy for preeclampsia found nifedipine and labetalol among the most effective agents in network meta-analysis. These reinforce the current first-line status of labetalol and nifedipine.
Quick Summary Table
| Setting | First-Line | Alternative |
|---|---|---|
| Chronic HTN (oral, long-term) | Methyldopa, Labetalol, Nifedipine | Metoprolol, HCTZ |
| Acute severe HTN (IV/urgent) | Labetalol IV, Nifedipine oral | Hydralazine IV, Nicardipine IV |
| Breastfeeding | Methyldopa, Labetalol | Enalapril/captopril |
| Avoid | ACEi, ARBs (2nd/3rd tri), Atenolol, Nitroprusside (prolonged) |
This is a shared conversation. Sign in to Orris to start your own chat.